Sector News

Categories

Borderless Insights

Image
Negotiating Terms with a New Employer
Image
Beyond Flowers and Platitudes: Reclaiming the Essence of International Women’s Day
Image
Visionary or ‘Stuck-in-the-Mud’? Where are you on Workplace Flexibility?

Flailing Wilex finds a lifeline as Roche steps in with an ADC deal

October 14, 2014
Life sciences
Germany’s Wilex has long been on the way out of biotech, but a new collaboration with Roche provides the company with some cash up front and a shot at down-the-line royalties.
 
Under the deal, Roche has agreed to pay as much as €52 million ($65.8 million) for the exclusive rights to an undisclosed tumor target. Roche also extended its relationship with Heidelberg Pharma, Wilex’s CRO subsidiary that out-licenses the biotech’s proprietary antibody-drug conjugate technology.
 
Wilex didn’t say how much of the sum comes in the form of up-front cash, but, for a company that has spent the past year struggling to keep the doors open, any income is a positive.
 
The Munich company’s problems began in 2012, when Rencarex, a renal cell carcinoma treatment, failed a Phase III trial. After a year of “intensive efforts” to find investors, Wilex let go of 80% of its staff in January and unveiled plans to gradually exit all clinical development, transitioning into a service provider.
 
So far, the company has signed over the Chinese rights to the Phase II pancreatic and breast cancer treatment Mesupron in a €7 million ($9.6 million) deal with Link Health, trading rest-of-the-world ownership of the drug to Israel’s RedHill Biopharma for $1 million up front and future royalties. And, in May, Wilex handed back 5 once-promising cancer treatments to ex-partner UCB in exchange for cancellation fees and some debt forgiveness.
 
Wilex co-founder and CEO Olaf Wilhelm stepped down in March after about 17 years with the company, replaced by CFO Jan Schmidt-Brand. The company, a Fierce 15 honoree back in 2005, was originally launched with the help of German billionaire Dietmar Hopp.
 
By Damian Garde
 
 

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

Read more
April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

Read more
April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

Read more
More news

How can we help you?

We're easy to reach